Clinical trial
An Open-Label, Multicenter, Phase Ib Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Cevostamab in Patients With Systemic Lupus Erythematosus With or Without Active Lupus Nephritis
NCT07629583 is registered in ClinicalTrials.gov with Genentech, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Open-Label, Multicenter, Phase Ib Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Cevostamab in Patients With Systemic Lupus Erythematosus With or Without Active Lupus Nephritis
- Lead sponsor
- Genentech, Inc.
- Phase
- Phase 1
- Overall status
- Recruiting
- Start date
- October 31, 2026
- Completion date
- March 29, 2030
- Enrollment
- 46 (estimated)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.